Interstitial Lung Disease clinical trials

Explore recruiting interstitial lung disease clinical trials.

Recruiting interstitial lung disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Interstitial Lung Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)

Belgium, Germany, Denmark, Italy, France, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis

Hungary, Romania, Poland, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (CTD).

Belgium, Netherlands, Germany, France, Greece, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

Greece, France, Netherlands, Italy, Spain, Czechia +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease related to systemic sclerosis: a multicentre double-blind placebo-controlled randomized trial.

France

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

Belgium, Italy, Spain, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Interstitial Lung Disease trials by city

Interstitial Lung Disease in Toronto Interstitial Lung Disease in Vancouver Interstitial Lung Disease in Montreal Interstitial Lung Disease in Calgary Interstitial Lung Disease in Edmonton Interstitial Lung Disease in Ottawa Interstitial Lung Disease in Winnipeg Interstitial Lung Disease in Quebec City Interstitial Lung Disease in Hamilton Interstitial Lung Disease in Kitchener Interstitial Lung Disease in London Interstitial Lung Disease in Halifax Interstitial Lung Disease in New York Interstitial Lung Disease in Los Angeles Interstitial Lung Disease in Chicago Interstitial Lung Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease